Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

NCT00528528 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913 ·Status: TERMINATED ·Phase: PHASE3

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01415141 ·Status: WITHDRAWN ·Phase: PHASE4

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118 ·Status: COMPLETED ·Phase: PHASE3

Virology Follow up Study in Subjects Previously Treated With Telaprevir

NCT00916474 ·Status: COMPLETED

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

NCT00446134 ·Status: COMPLETED ·Phase: PHASE2

Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

NCT01727934 ·Status: UNKNOWN ·Phase: PHASE2

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

NCT01384383 ·Status: TERMINATED ·Phase: PHASE2

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

NCT00580801 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

NCT01754974 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

NCT00561015 ·Status: COMPLETED ·Phase: PHASE2

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

NCT01646489 ·Status: COMPLETED ·Phase: PHASE1

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130 ·Status: COMPLETED

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

NCT00215865 ·Status: COMPLETED ·Phase: PHASE3

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

NCT01185860 ·Status: COMPLETED ·Phase: PHASE1

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

NCT01353248 ·Status: COMPLETED ·Phase: PHASE2

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

NCT02465203 ·Status: TERMINATED ·Phase: PHASE3

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

NCT00910624 ·Status: COMPLETED ·Phase: PHASE3

Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

NCT00532701 ·Status: COMPLETED ·Phase: PHASE4

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760 ·Status: COMPLETED ·Phase: PHASE3

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420 ·Status: COMPLETED ·Phase: PHASE2

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

NCT00255034 ·Status: TERMINATED ·Phase: PHASE4

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

NCT01718158 ·Status: COMPLETED ·Phase: PHASE3